To the IMSMP Family and Supporters of the Tisch MS Research Center of New York,  It gives me great pride and joy to announce that the FDA has approved our Phase I clinical trial for the use of bone marrow-derived neural stem cells in the treatment of multiple sclerosis. This exciting development is the culmination of a decade long effort by the dedicated team of scientists at the Tisch MS Research Center of New York at a cost of several million dollars. In treating patients with MS, especially those with progressive disease, the inability to repair disability presents an enormous challenge.  Almost yearly new treatment choices become available for disease activity but no current therapy has the potential to reverse established disability.  At the Tisch MS Research Center, our research efforts are in part directed at resolving this vexing problem.  The principal drivers of this effort are our long suffering patients who over the years have given us their unwavering support. The inspiration that we receive from our patients helps propel us past the various obstacles and hindrances.  The level of dignity and immeasurable fortitude with which our patients overcome tasks that most people take for granted along with their loyalty, inspiration, hope, and love allows us to remain steadfast in this seemingly never-ending process. Your unfaltering spirit and continuous faith in our efforts in stem cell research has been critical and for that we are truly grateful.  The Phase I FDA-approved  clinical trial represents the laying of the cornerstone to the foundation of “repairing“ the nervous system, allowing even those with the most severe cases to persevere in their knowledge that their daily struggles may one day be ameliorated. This is the dawn of a new light so that a lessening of the suffering endured by the many MS patients worldwide may be envisaged.  Many obstacles remain and the future is uncertain, but at least we are now embarking on a journey together toward a long sought destination.   Much scientific work will be needed in the future to resolve many unanswered questions. The research laboratory and clinical team lead by Dr. Violaine K. Harris and I will continue to tirelessly work on these issues.  This FDA approval renews our spirit and our endeavor to work toward our ultimate goal of “a future without MS.” The process of obtaining Institutional Review Board (IRB) approval and funding for our study has already begun, with the aim to commence this Phase I clinical trial by the end of the year. We will continue to provide updates to this study and our findings throughout the trial on the Tisch MS Research Center’s website.    

Warmest Regards,

Saud A. Sadiq, MD

A scientific summary of the study, information on the protocol and detail about participation, is posted at www.tischms.org  

To view the full press release, please click file attachment below or go to "press releases."

Special presentations will be made by the Tisch MS Research Stem Cell Team at this year’s annual patient symposium on Sunday, October 13, 2013 at the New York Hilton Midtown.